tetano
Editor, Senior Moderator
Stem Cells Transl Med
. 2021 Jul 24.
doi: 10.1002/sctm.21-0183. Online ahead of print.
SARS-CoV-2 research using human pluripotent stem cells and organoids
Sayaka Deguchi[SUP] 1 [/SUP], Ángel Serrano-Aroca[SUP] 2 [/SUP], Murtaza M Tambuwala[SUP] 3 [/SUP], Bruce D Uhal[SUP] 4 [/SUP], Adam M Brufsky[SUP] 5 [/SUP], Kazuo Takayama[SUP] 1 [/SUP]
Affiliations
Abstract
Experimental cell models are indispensable for clarifying the pathophysiology of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and for developing therapeutic agents. To recapitulate the symptoms and drug response of COVID-19 patients in vitro, SARS-CoV-2 studies using physiologically relevant human embryonic stem (ES)/induced pluripotent stem (iPS) cell-derived somatic cells and organoids are ongoing. These cells and organoids have been used to show that SARS-CoV-2 can infect and damage various organs including the lung, heart, brain, intestinal tract, kidney, and pancreas. They are also being used to develop COVID-19 therapeutic agents, including evaluation of their antiviral efficacy and safety. The relationship between COVID-19 aggravation and human genetic backgrounds has been investigated using genetically modified ES/iPS cells and patient-derived iPS cells. This review summarizes the latest results and issues of SARS-CoV-2 research using human ES/iPS cell-derived somatic cells and organoids.
Keywords: COVID-19; SARS-CoV-2; human ES cells; human iPS cells; organoids.
. 2021 Jul 24.
doi: 10.1002/sctm.21-0183. Online ahead of print.
SARS-CoV-2 research using human pluripotent stem cells and organoids
Sayaka Deguchi[SUP] 1 [/SUP], Ángel Serrano-Aroca[SUP] 2 [/SUP], Murtaza M Tambuwala[SUP] 3 [/SUP], Bruce D Uhal[SUP] 4 [/SUP], Adam M Brufsky[SUP] 5 [/SUP], Kazuo Takayama[SUP] 1 [/SUP]
Affiliations
- PMID: 34302450
- DOI: 10.1002/sctm.21-0183
Abstract
Experimental cell models are indispensable for clarifying the pathophysiology of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and for developing therapeutic agents. To recapitulate the symptoms and drug response of COVID-19 patients in vitro, SARS-CoV-2 studies using physiologically relevant human embryonic stem (ES)/induced pluripotent stem (iPS) cell-derived somatic cells and organoids are ongoing. These cells and organoids have been used to show that SARS-CoV-2 can infect and damage various organs including the lung, heart, brain, intestinal tract, kidney, and pancreas. They are also being used to develop COVID-19 therapeutic agents, including evaluation of their antiviral efficacy and safety. The relationship between COVID-19 aggravation and human genetic backgrounds has been investigated using genetically modified ES/iPS cells and patient-derived iPS cells. This review summarizes the latest results and issues of SARS-CoV-2 research using human ES/iPS cell-derived somatic cells and organoids.
Keywords: COVID-19; SARS-CoV-2; human ES cells; human iPS cells; organoids.